search
Back to results

Time Limited Eating in Type 1 Diabetes (TLET1D)

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Time Limited Eating
Sponsored by
Children's Hospital Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring Type 1 Diabetes, Time Limited Eating, β-cell

Eligibility Criteria

12 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • includes age of 12-25 years
  • T1D diagnosed within 6 months
  • at least one positive pancreatic antibody including glutamic acid decarboxylase (GAD) antibody, islet tyrosine phosphatase 2 (IA2) antibody, or insulin antibody
  • can be on either insulin injections or insulin pump
  • can be of any BMI status
  • can speak any language

Exclusion Criteria:

  • negative pancreatic antibodies
  • unwillingness to wear a CGM

Sites / Locations

  • Children's Hospital Los Angeles

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control - Standard Care

Intervention - Time Limited Eating

Arm Description

includes a minimum 12-hour feeding window for 7 days per week no caloric restriction will be used will wear a continuous glucose monitor

includes an 8-hour feed/16-hour fast for 7 days per week will be instructed to consume all of their calories in the afternoon/evening period can consume non-caloric beverages (water, tea, coffee) during the fasting period will wear a continuous glucose monitor no caloric restriction will be used

Outcomes

Primary Outcome Measures

Acceptability and feasibility of intervention, as indicated by the "Intervention Satisfaction Survey"
Likert scale "Agree strongly" is 1, "Agree" is 2, "Neutral" is 3, "Disagree" is 4, and "Disagree strongly" is 5. Lower scores indicate more satisfaction, higher scores indicate low satisfaction.
Change in β-cell function at 9 weeks, as indicated by mixed meal tolerance test with C-peptide levels
C-peptide and glucose levels will be performed at baseline and 60-, 90-, and 120-minutes post-meal. Baseline plasma C-peptide concentration divided by the baseline plasma glucose concentration will be calculated as a pragmatic marker of β-cell function. The area under the stimulated C-peptide curve will then be calculated, which will be the primary outcome examined.
Change in glycemic control at 9 weeks, as indicated by continuous glucose monitoring (percent time in range), and HbA1c
Continuous glucose monitors will be worn for duration of the study, glycemic control will be evaluated using percent time in range. HbA1c will reflect glycemic control over time.
Safety, as indicated by hypoglycemia
Hypoglycemia will be defined as blood sugar < 70 mg/dL on continuous glucose monitor. Frequency and severity of hypoglycemia will be used to assess safety of intervention.

Secondary Outcome Measures

Dietary patterns, as indicated by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
24-hour dietary recall, ~30 minutes to complete.
Quality of life, as indicated by Pediatric Quality of Life Inventory (PedsQL), Diabetes Module
Likert scale "Never" is 0, "Almost Never" is 1, "Sometimes" is 2, "Often" is 3, and "Almost Always" is 4
Stress level, as indicated by Perceived Stress Scale
Likert scale "Never" is 0, "Almost Never" is 1, "Sometimes" is 2, "Fairly Often" is 3, and "Very Often" is 4
Binge Eating, as indicated by Binge Eating Disorder Screener
Likert scale "Never or rarely" is 0, "Sometimes" is 1, "Often" is 2, "Always" is 3. Additionally, two yes or no questions.
Anxiety, as indicated by Neuro-QOL-Anxiety-Short Form
Likert scale "Never" is 1, "Rarely" is 2, "Sometimes" is 3, "Often" is 4, "Always" is 5
Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)
Assessment of sleep schedule, school schedule, time spent outdoors. Multiple choice and open-ended questions.

Full Information

First Posted
August 1, 2021
Last Updated
August 14, 2023
Sponsor
Children's Hospital Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT05031429
Brief Title
Time Limited Eating in Type 1 Diabetes
Acronym
TLET1D
Official Title
Time Limited Eating in New-Onset Type 1 Diabetes: Feasibility, Acceptability, and Effect on β-cell Function
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
June 13, 2023 (Actual)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Hospital Los Angeles

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized-control pilot study that aims to evaluate Time Limited Eating (TLE) in the pediatric T1D population, implemented within the first six months after diagnosis. This period is characterized by residual β-cell function, during which TLE may have the ability to preserve and improve β-cell activity, indicated by increased C-peptide production. The investigators aim to assess the feasibility, acceptability, and safety of TLE in the pediatric T1D population, as well as to investigate the impact of TLE on β-cell function, insulin sensitivity, and glycemic control.
Detailed Description
This will be a two-armed study with an intervention and control group. Feasibility and acceptability will be assessed by using questionnaires. Safety will be indicated by hypoglycemia occurrence. β-cell function and insulin sensitivity will be evaluated using mixed meal tolerance test with C-peptide and glucose levels. Glycemic control will be indicated by continuous glucose monitor (CGM). Block randomization will be utilized to ensure the groups are balanced in terms of BMI. The study period will be 9 weeks in duration, including a week-long run-in period and an 8-week intervention period. There will be two in-person study visits at week 0 and week 9. Anthropometrics including weight, height, and pubertal status will be evaluated at these times. Group 1- Standard Care (control) includes a minimum 12-hour feeding window for 7 days per week no caloric restriction will be used will wear a continuous glucose monitor Group 2 - TLE (intervention) includes an 8-hour feed/16-hour fast for 7 days per week will be instructed to consume all of their calories in the afternoon/evening period can consume non-caloric beverages (water, tea, coffee) during the fasting period will wear a continuous glucose monitor no caloric restriction will be used

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Type 1 Diabetes, Time Limited Eating, β-cell

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control - Standard Care
Arm Type
No Intervention
Arm Description
includes a minimum 12-hour feeding window for 7 days per week no caloric restriction will be used will wear a continuous glucose monitor
Arm Title
Intervention - Time Limited Eating
Arm Type
Experimental
Arm Description
includes an 8-hour feed/16-hour fast for 7 days per week will be instructed to consume all of their calories in the afternoon/evening period can consume non-caloric beverages (water, tea, coffee) during the fasting period will wear a continuous glucose monitor no caloric restriction will be used
Intervention Type
Other
Intervention Name(s)
Time Limited Eating
Intervention Description
Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
Primary Outcome Measure Information:
Title
Acceptability and feasibility of intervention, as indicated by the "Intervention Satisfaction Survey"
Description
Likert scale "Agree strongly" is 1, "Agree" is 2, "Neutral" is 3, "Disagree" is 4, and "Disagree strongly" is 5. Lower scores indicate more satisfaction, higher scores indicate low satisfaction.
Time Frame
At end of study (at 9 weeks)
Title
Change in β-cell function at 9 weeks, as indicated by mixed meal tolerance test with C-peptide levels
Description
C-peptide and glucose levels will be performed at baseline and 60-, 90-, and 120-minutes post-meal. Baseline plasma C-peptide concentration divided by the baseline plasma glucose concentration will be calculated as a pragmatic marker of β-cell function. The area under the stimulated C-peptide curve will then be calculated, which will be the primary outcome examined.
Time Frame
Baseline and 9 weeks
Title
Change in glycemic control at 9 weeks, as indicated by continuous glucose monitoring (percent time in range), and HbA1c
Description
Continuous glucose monitors will be worn for duration of the study, glycemic control will be evaluated using percent time in range. HbA1c will reflect glycemic control over time.
Time Frame
Up to 9 weeks; HbA1c: Baseline and 9 weeks
Title
Safety, as indicated by hypoglycemia
Description
Hypoglycemia will be defined as blood sugar < 70 mg/dL on continuous glucose monitor. Frequency and severity of hypoglycemia will be used to assess safety of intervention.
Time Frame
Up to 9 weeks
Secondary Outcome Measure Information:
Title
Dietary patterns, as indicated by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
Description
24-hour dietary recall, ~30 minutes to complete.
Time Frame
Baseline, 9 weeks
Title
Quality of life, as indicated by Pediatric Quality of Life Inventory (PedsQL), Diabetes Module
Description
Likert scale "Never" is 0, "Almost Never" is 1, "Sometimes" is 2, "Often" is 3, and "Almost Always" is 4
Time Frame
Baseline and 9 weeks
Title
Stress level, as indicated by Perceived Stress Scale
Description
Likert scale "Never" is 0, "Almost Never" is 1, "Sometimes" is 2, "Fairly Often" is 3, and "Very Often" is 4
Time Frame
Baseline and 9 weeks
Title
Binge Eating, as indicated by Binge Eating Disorder Screener
Description
Likert scale "Never or rarely" is 0, "Sometimes" is 1, "Often" is 2, "Always" is 3. Additionally, two yes or no questions.
Time Frame
Baseline and 9 weeks
Title
Anxiety, as indicated by Neuro-QOL-Anxiety-Short Form
Description
Likert scale "Never" is 1, "Rarely" is 2, "Sometimes" is 3, "Often" is 4, "Always" is 5
Time Frame
Baseline and 9 weeks
Title
Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)
Description
Assessment of sleep schedule, school schedule, time spent outdoors. Multiple choice and open-ended questions.
Time Frame
Baseline and 9 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: includes age of 12-25 years T1D diagnosed within 6 months at least one positive pancreatic antibody including glutamic acid decarboxylase (GAD) antibody, islet tyrosine phosphatase 2 (IA2) antibody, or insulin antibody can be on either insulin injections or insulin pump can be of any BMI status can speak any language Exclusion Criteria: negative pancreatic antibodies unwillingness to wear a CGM
Facility Information:
Facility Name
Children's Hospital Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32320147
Citation
Gabel K, Varady KA. Feasibility of Time-Restricted Eating. Obesity (Silver Spring). 2020 May;28(5):860. doi: 10.1002/oby.22785. No abstract available.
Results Reference
background
PubMed Identifier
30216730
Citation
Gabel K, Hoddy KK, Varady KA. Safety of 8-h time restricted feeding in adults with obesity. Appl Physiol Nutr Metab. 2019 Jan;44(1):107-109. doi: 10.1139/apnm-2018-0389. Epub 2018 Sep 14.
Results Reference
background
PubMed Identifier
32673591
Citation
Cienfuegos S, Gabel K, Kalam F, Ezpeleta M, Wiseman E, Pavlou V, Lin S, Oliveira ML, Varady KA. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. Cell Metab. 2020 Sep 1;32(3):366-378.e3. doi: 10.1016/j.cmet.2020.06.018. Epub 2020 Jul 15.
Results Reference
background
PubMed Identifier
31813824
Citation
Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, Wang X, Fleischer JG, Navlakha S, Panda S, Taub PR. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metab. 2020 Jan 7;31(1):92-104.e5. doi: 10.1016/j.cmet.2019.11.004. Epub 2019 Dec 5.
Results Reference
background
PubMed Identifier
23520370
Citation
Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013 Apr;36(4):1047-55. doi: 10.2337/dc12-1805. No abstract available.
Results Reference
background
PubMed Identifier
29754952
Citation
Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab. 2018 Jun 5;27(6):1212-1221.e3. doi: 10.1016/j.cmet.2018.04.010. Epub 2018 May 10.
Results Reference
background
PubMed Identifier
31002478
Citation
Hutchison AT, Regmi P, Manoogian ENC, Fleischer JG, Wittert GA, Panda S, Heilbronn LK. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity (Silver Spring). 2019 May;27(5):724-732. doi: 10.1002/oby.22449. Epub 2019 Apr 19.
Results Reference
background
PubMed Identifier
32270927
Citation
Chow LS, Manoogian ENC, Alvear A, Fleischer JG, Thor H, Dietsche K, Wang Q, Hodges JS, Esch N, Malaeb S, Harindhanavudhi T, Nair KS, Panda S, Mashek DG. Time-Restricted Eating Effects on Body Composition and Metabolic Measures in Humans who are Overweight: A Feasibility Study. Obesity (Silver Spring). 2020 May;28(5):860-869. doi: 10.1002/oby.22756. Epub 2020 Apr 9.
Results Reference
background
PubMed Identifier
31151228
Citation
Jamshed H, Beyl RA, Della Manna DL, Yang ES, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans. Nutrients. 2019 May 30;11(6):1234. doi: 10.3390/nu11061234.
Results Reference
background
Citation
Center for Disease and Control Prevention. Incidence of newly diagnosed diabetes. https://www.cdc.gov/diabetes/data/statistics-report/newly-diagnosed-diabetes.html. 2020; Accessed April 25, 2021.
Results Reference
background
PubMed Identifier
29559451
Citation
Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ. Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. Diabetes Care. 2018 Apr;41(4):653-661. doi: 10.2337/dc17-0806.
Results Reference
background
PubMed Identifier
29735574
Citation
Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, Rhodes ET, Ebbeling CB, Westman EC, Yancy WS Jr, Ludwig DS. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. Pediatrics. 2018 Jun;141(6):e20173349. doi: 10.1542/peds.2017-3349. Epub 2018 May 7.
Results Reference
background
PubMed Identifier
31393762
Citation
de Souza Bosco Paiva C, Lima MHM. Introducing a very low carbohydrate diet for a child with type 1 diabetes. Br J Nurs. 2019 Aug 8;28(15):1015-1019. doi: 10.12968/bjon.2019.28.15.1015.
Results Reference
background
PubMed Identifier
33521039
Citation
Calabrese CM, Valentini A, Calabrese G. Gut Microbiota and Type 1 Diabetes Mellitus: The Effect of Mediterranean Diet. Front Nutr. 2021 Jan 13;7:612773. doi: 10.3389/fnut.2020.612773. eCollection 2020.
Results Reference
background
PubMed Identifier
32682994
Citation
Vidmar AP, Goran MI, Naguib M, Fink C, Wee CP, Hegedus E, Lopez K, Gonzalez J, Raymond JK. Time limited eating in adolescents with obesity (time LEAd): Study protocol. Contemp Clin Trials. 2020 Aug;95:106082. doi: 10.1016/j.cct.2020.106082. Epub 2020 Jul 16.
Results Reference
background
PubMed Identifier
28853981
Citation
Liu H, Javaheri A, Godar RJ, Murphy J, Ma X, Rohatgi N, Mahadevan J, Hyrc K, Saftig P, Marshall C, McDaniel ML, Remedi MS, Razani B, Urano F, Diwan A. Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. Autophagy. 2017;13(11):1952-1968. doi: 10.1080/15548627.2017.1368596. Epub 2017 Nov 25.
Results Reference
background
PubMed Identifier
26094889
Citation
Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015 Jul 7;22(1):86-99. doi: 10.1016/j.cmet.2015.05.012. Epub 2015 Jun 18.
Results Reference
background
PubMed Identifier
28235195
Citation
Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, Cohen P, Sneddon JB, Perin L, Longo VD. Fasting-Mimicking Diet Promotes Ngn3-Driven beta-Cell Regeneration to Reverse Diabetes. Cell. 2017 Feb 23;168(5):775-788.e12. doi: 10.1016/j.cell.2017.01.040.
Results Reference
background
PubMed Identifier
30657336
Citation
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18. Erratum In: Diabetes Technol Ther. 2019 Apr;21(4):230.
Results Reference
background
PubMed Identifier
26164381
Citation
DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, Schwab KO, Holl RW, Hofer SE, Maahs DM; Type 1 Diabetes Exchange Clinic Network and Diabetes Prospective Follow-up Registry. Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. J Pediatr. 2015 Sep;167(3):627-32.e1-4. doi: 10.1016/j.jpeds.2015.05.046. Epub 2015 Jul 8.
Results Reference
background
PubMed Identifier
33402367
Citation
Tommerdahl KL, Baumgartner K, Schafer M, Bjornstad P, Melena I, Hegemann S, Baumgartner AD, Pyle L, Cree-Green M, Truong U, Browne L, Regensteiner JG, Reusch JEB, Nadeau KJ. Impact of Obesity on Measures of Cardiovascular and Kidney Health in Youth With Type 1 Diabetes as Compared With Youth With Type 2 Diabetes. Diabetes Care. 2021 Mar;44(3):795-803. doi: 10.2337/dc20-1879. Epub 2021 Jan 5.
Results Reference
background
PubMed Identifier
24026551
Citation
Bjornstad P, Snell-Bergeon JK, Rewers M, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes. Diabetes Care. 2013 Nov;36(11):3678-83. doi: 10.2337/dc13-0631. Epub 2013 Sep 11.
Results Reference
background
PubMed Identifier
30566007
Citation
Bjornstad P, Schafer M, Truong U, Cree-Green M, Pyle L, Baumgartner A, Garcia Reyes Y, Maniatis A, Nayak S, Wadwa RP, Browne LP, Reusch JEB, Nadeau KJ. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus. Circulation. 2018 Dec 18;138(25):2895-2907. doi: 10.1161/CIRCULATIONAHA.118.035525.
Results Reference
background
PubMed Identifier
30652426
Citation
Ruan Y, Willemsen RH, Wilinska ME, Tauschmann M, Dunger DB, Hovorka R. Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration. Pediatr Diabetes. 2019 May;20(3):282-285. doi: 10.1111/pedi.12816. Epub 2019 Feb 19.
Results Reference
background
PubMed Identifier
16990662
Citation
Shim WS, Kim SK, Kim HJ, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol. 2006 Oct;155(4):615-22. doi: 10.1530/eje.1.02249.
Results Reference
background
PubMed Identifier
27981043
Citation
Paglialunga S, Guerrero A, Roessig JM, Rubin P, Dehn CA. Adding to the spectrum of insulin sensitive populations for mixed meal tolerance test glucose reliability assessment. J Diabetes Metab Disord. 2016 Dec 7;15:57. doi: 10.1186/s40200-016-0279-x. eCollection 2016.
Results Reference
background
PubMed Identifier
27407117
Citation
Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health beta-Cell Project Team. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of beta-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.
Results Reference
background
PubMed Identifier
3899825
Citation
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. doi: 10.1007/BF00280883.
Results Reference
background
PubMed Identifier
7033284
Citation
Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981 Dec;68(6):1456-67. doi: 10.1172/jci110398.
Results Reference
background
PubMed Identifier
31127824
Citation
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4356-4364. doi: 10.1210/jc.2018-02763. Erratum In: J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1775-e1776.
Results Reference
background
Citation
Harnack L. Nutrition Data System for Research (NDSR). In: Gellman M.D., Turner J.R. (eds) Encyclopedia of Behavioral Medicine. Springer. 2013.
Results Reference
background
Citation
Raper N, Perloff B, Ingwerson L, Steinfeldt L, Anand J. An overview of USDA's Dietary Intake Data System. Journal of Food Composition and Analysis. 2004;17(3-4):545-555.
Results Reference
background
PubMed Identifier
24815959
Citation
Hood KK, Beavers DP, Yi-Frazier J, Bell R, Dabelea D, Mckeown RE, Lawrence JM. Psychosocial burden and glycemic control during the first 6 years of diabetes: results from the SEARCH for Diabetes in Youth study. J Adolesc Health. 2014 Oct;55(4):498-504. doi: 10.1016/j.jadohealth.2014.03.011. Epub 2014 May 10.
Results Reference
background
PubMed Identifier
27558207
Citation
Ivezaj V, White MA, Grilo CM. Examining binge-eating disorder and food addiction in adults with overweight and obesity. Obesity (Silver Spring). 2016 Oct;24(10):2064-9. doi: 10.1002/oby.21607. Epub 2016 Aug 25.
Results Reference
background
PubMed Identifier
12900694
Citation
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.
Results Reference
background
PubMed Identifier
32455345
Citation
Vidmar AP, Goran MI, Raymond JK. Time-Limited Eating in Pediatric Patients with Obesity: A Case Series. J Food Sci Nutr Res. 2019;2(3):236-244. doi: 10.26502/jfsnr.2642-11000022. Epub 2019 Sep 20.
Results Reference
background

Learn more about this trial

Time Limited Eating in Type 1 Diabetes

We'll reach out to this number within 24 hrs